R&D A complex biological landscape of protein function unlocked ... Promise Bio’s advanced AI-driven system integrates proteomics and multi-omics data, focusing on PTMs to identify unique biomarkers % disease pathways.
R&D Clinical Trials Round-Up – Jan to Feb 2026 Read how Jan-Feb '26 offered a revealing cross-section of how R&D is evolving across therapy areas.
Oncology Advancing radiopharmaceutical development: Preclinical preci... Radiopharmaceutical development must move beyond fixed paradigms toward patient-specific, data-driven optimisation.
R&D What’s holding back precision medicine outside oncology? Precision medicine is finding success in cancer care, but not much elsewhere. The reasons why are often more economic than scientific.
R&D Precision medicine - closing the loop: What happens after th... We often talk about diagnostics as the gateway to precision medicine. But what happens before and after the test?
R&D Built for one: The case for custom formulation in the era of... The precision medicine market is projected to exceed $175 billion by 2030, reflecting continued growth and interest in innovative approaches that tailor therapeutics that accounts for diffe
News Novartis snaps up PI3Kα breast cancer drug in $3bn deal Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.